An official website of the United States government
NIH Websites Are Changing Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Trial Status: active
This trial investigates a new drug, EIS-12656, in participants with specified advanced
solid tumors carrying pre-specified mutations. The trial consists of a dose escalation
part (Phase 1) and a dose expansion part (Phase 2).
Inclusion Criteria
Homologous recombination deficient mutations
Recurrent locally advanced or metastatic solid tumors
Measurable disease (RECIST 1.1 Criteria)
Progressed on at least on prior line of treatment or intolerant to additional effective standard therapy
Life expectancy > 3 months
ECOG Performance Status 0 or 1
Adequate organ and bone marrow function
Exclusion Criteria
History or evidence of any clinically relevant gastrointestinal disease